Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.36 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312302 | 0.88 | SLC6A4 (0.46) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4836403 | 0.77 | SLC6A4 (0.43) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23780011 | 0.77 | CTSL (0.42) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6019029 | 0.77 | CTSL (0.42) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7306627 | 0.76 | ALDH1A1 (0.45) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6605312 | 0.74 | HTR2C (0.47) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL409358 | 0.74 | TDP1 (0.41) | — | |
| SCHEMBL1672995 | 0.74 | TDP1 (0.41) | — | |
| SCHEMBL9311330 | 0.72 | SLC6A4 (0.52) | OPRD1SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL9893193 | 0.72 | CTSL (0.42) | OPRD1HTR2CSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| EP-0874645-B1 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-0882010-B1 | PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-05-02 | — | — | EP | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | OPRD1 2763/4885HTR2C 4306/4885SLC6A4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.